Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics
Allyson J. Ocean(Dana-Farber Cancer Institute), David M. Goldenberg(Unknown), William A. Wegener(Children's Hospital of Philadelphia), Aditya Bardia(UCLA Health), Vincent J. Picozzi(Virginia Mason Medical Center), Robert M. Sharkey(Immunomedics (United States)), Serengulam V. Govindan(Dana-Farber Cancer Institute), Linda T. Vahdat(Dartmouth–Hitchcock Medical Center), Ingrid A. Mayer(Vanderbilt University), Pius Maliakal(Dana-Farber Cancer Institute), Wells A. Messersmith(University of Colorado Cancer Center), Steven J. Isakoff(Harvard University), Alexander Starodub(Dana-Farber Cancer Institute), Michael J. Guarino(Dana-Farber Cancer Institute)
Cited by 235
Related Papers
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
|Cell|2014|2.5k
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
|Science|2013|2.5k
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
|Nature|2015|1.8k
Connecting copper and cancer: from transition metal signalling to metalloplasia
|Nature reviews. Cancer|2021|1.3k